Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

	As of September 30, 2019				Fair Value Measurements
	Carrying		Fair		As of September 30, 2019
	Amount		Value		Level 1		Level 2		Level 3
					(unaudited)
Liabilities:
Contingent consideration:
Asuragen (1)	$	3,024	$	3,024	$	-	$	-	$	3,024
Other long-term liabilities:
Warrant liability (2)		326		326		-		-		326
	$	3,350	$	3,350	$	-	$	-	$	3,350

	As of December 31, 2018				Fair Value Measurements
	Carrying		Fair		As of December 31, 2018
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen (1)	$	3,127	$	3,127	$	-	$	-	$	3,127
Other long-term liabilities:
Warrant liability (2)		361		361		-		-		361
	$	3,488	$	3,488	$	-	$	-	$	3,488

⁽¹⁾⁽²⁾ See Note 9, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the Contingent Consideration Liability and the Underwriters’ Warrants to September 30, 2019 is as follows:

								Cancellation		Adjustment
								of Obligation/		to Fair Value/
	December 31, 2018		Payments			Accretion		Conversions Exercises		Mark to Market			September 30, 2019
	(unaudited)
Asuragen	$	3,127	$	(434	)	$	331	$	-	$	-		$	3,024
Underwriters Warrants		361		-			-		-		(35	)		326
	$	3,488	$	(434	)	$	331	$	-	$	(35	)	$	3,350